Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeWages, Salaries and Other
Others
Ratios

Sagimet Biosciences (SGMT) Research & Development (2023 - 2024)

Sagimet Biosciences (SGMT) has 2 years of Research & Development data on record, last reported at $14.2 million in Q4 2024.

  • For Q4 2024, Research & Development rose 151.34% year-over-year to $14.2 million; the TTM value through Dec 2024 reached $38.4 million, up 94.39%, while the annual FY2025 figure was $39.1 million, 1.59% up from the prior year.
  • Research & Development reached $14.2 million in Q4 2024 per SGMT's latest filing, up from $12.7 million in the prior quarter.
  • Across five years, Research & Development topped out at $14.2 million in Q4 2024 and bottomed at $4.5 million in Q1 2023.